ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/SA/5000-Adelaide-Cancer-Research-SA
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
29
trial(s) found.
NCT07238075
Advanced
Phase 1
Recruiting
A First-in-human, Multicenter Dose Escalation and Multiple Cohort Expansion Phase 1a/b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ADCX-020 in Participants With Locally Advanced or Metastatic Solid Tumors (
ADCX-020-01
)
antibody-drug conjugate,unknown target
Cancer
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4215 - Southport - Tasman Oncology
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - Linear Clinical Research
NCT07226427
Advanced
Phase 1
Recruiting
A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, as Monotherapy in Participants With Platinum-Resistant Ovarian Cancer (
MEN2501-01
)
KIF18A inhibitor
Platinum resistant ovarian cancer
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Cancer Research SA
NCT07222267
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75202, Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors (
BG-75202-101
)
KAT6A/B inhibitor
Breast cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5000 - Adelaide - Cancer Research SA
NCT07195916
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies (
INCA036873-101
)
bispecific T-cell engager,CD70-targeting
Haematological malignancy
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Cancer Research SA
NCT07181681
Advanced
Phase 1
Recruiting
A Phase 1a/b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C0902, an Antibody-Drug Conjugate Targeting Epidermal Growth Factor Receptor (EGFR) × Mesenchymal-Epithelial Transition (MET), Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors (
BG-C0902-101
)
anti-EGFR/cMET antibody-drug conjugate
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Cancer Research SA
NCT07147348
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, First-in-human, Open-label, Dose Escalation and Indication Expansion Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors (
BNT3212-01
)
bispecific PD-L1/VEGFA antibody
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - One Clinical Research
NCT07111520
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Multi-site, Open-label, Dose Finding Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT326 in Combination With BNT327 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (
BNT326-02
)
anti-ERBB3 antibody-drug conjugate
bispecific PD-L1/VEGFA antibody
Non-small cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Private Hospital
QLD
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Cancer Research SA
NCT07100106
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination With Giredestrant in Comparison With Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer Who Have Previously Progressed During or After a CDK4/6 Inhibitor (
MoonROSE
)
CDK2/4/6 inhibitor
CDK4/6 inhibitor
selective estrogen receptor degrader
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
SA
5000 - Adelaide - Cancer Research SA
NCT07070232
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors (
BNT326-01
)
anti-ERBB3 antibody-drug conjugate
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Gastroesophageal junction adenocarcinoma
Melanoma
Mucosal melanoma
Non-small cell lung cancer
Solid tumour
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - One Clinical Research
NCT07023627
Advanced
Phase 2
Recruiting
A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1) (
MAESTRA-1
)
CDK2 inhibitor
Ovarian cancer
NSW
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
SA
5000 - Adelaide - Cancer Research SA
5065 - Toorak Gardens - Burnside War Memorial Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06841055
Advanced
Phase 2
Recruiting
A Phase II, Multisite, Open-label Trial of Pumitamig (BNT327) in Combination With Standard-of-care Chemotherapy in First-line and Second-line Non-small Cell Lung Cancer (NSCLC) (
BNT327-07
)
bispecific PD-L1/VEGFA antibody
Non-small cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - Hollywood Private Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06827236
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer (
BNT323-03
)
bispecific PD-L1/VEGFA antibody
Breast cancer
SA
5000 - Adelaide - Cancer Research SA
NCT06819735
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicentre, Open-label Clinical Trial of DT-7012 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Selected Advanced Solid Tumors (
DOMISOL
, DOmain_therapeutics Monoclonal antIbody for SOLid Tumors)
anti-CCR8 monoclonal antibody
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - One Clinical Research
NCT06801834
Advanced
Phase 3
Recruiting
A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC) (
EVOKE-SCLC-04
)
anti-Trop2 antibody-drug conjugate
Small-cell lung cancer
NSW
2500 - Wollongong - Cancer Care Wollongong
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06750185
Advanced
Phase 1
Recruiting
A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors (
BNT317-01
)
cancer therapy,undisclosed mechanism
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Cancer Research SA
NCT06712316
Advanced
Phase 2 / Phase 3
Recruiting
A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer (
BNT327-06
)
bispecific PD-L1/VEGFA antibody
Non-small cell lung cancer
NSW
2500 - Wollongong - Cancer Care Wollongong
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
2830 - Dubbo - Dubbo Base Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4812 - Hyde Park - Icon Cancer Centre Townsville
4870 - Cairns - Cairns Base Hospital
SA
5000 - Adelaide - Cancer Research SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
NCT06672185
Advanced
Phase 1
Recruiting
A Phase 1 Study of ARC101 in Advanced Solid Tumors (
ARC101-P1-101
)
bispecific T-cell engager,CLDN6-targeting
Solid tumour
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5000 - Adelaide - Cancer Research SA
NCT06596473
Advanced
Phase 1
Recruiting
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors (
BG-C477-101
)
anti-CEACAM5 antibody-drug conjugate
Solid tumour
NSW
2086 - Frenchs Forest - Northern Beaches Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06533332
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1 Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of Escalating Doses of ERX-315 in Participants With Advanced Solid Tumors (
ERX-315-101
)
benzamide,ER alpha-targeting
Breast cancer
Endometrial cancer
Hepatocellular carcinoma
Ovarian cancer
Pancreatic cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
SA
5000 - Adelaide - Cancer Research SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06492616
Curative
Phase 3
Recruiting
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study (
ELEGANT
)
selective estrogen receptor degrader
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2060 - North Sydney - Mater Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2480 - Lismore - Lismore Base Hospital
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3135 - Ringwood East - Maroondah Hospital
3168 - Clayton - Monash Medical Centre
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4215 - Southport - ICON Cancer Care
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5000 - Adelaide - Cancer Research SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT06400472
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
anti-FR-alpha antibody-drug conjugate
Cervical cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Triple-negative breast cancer
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Cancer Research SA
NCT06349408
Advanced
Phase 1
Recruiting
A Phase 1 Study of IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors (
CIBI3001A101
)
bispecific EGFR/B7H3 antibody-drug conjugate
Solid tumour
NSW
2500 - Wollongong - Wollongong Hospital
SA
5000 - Adelaide - Cancer Research SA
NCT06340568
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer (
Fern-EC-01
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Endometrial cancer
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2500 - Wollongong - Wollongong Hospital
2541 - Nowra - Shoalhaven District Memorial Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Cancer Research SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06305962
Radonc
Phase 1
Recruiting
Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Solid Tumours (
177Lu-RAD204.2023.0001
)
radioconjugate,PD-L1-targeting
Cutaneous melanoma
Endometrial cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Small-cell lung cancer
Triple-negative breast cancer
NSW
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6150 - Murdoch - GenesisCare Murdoch
NCT05671510
Advanced
Phase 3
Recruiting
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors (
PRESERVE-003
)
anti-CTLA4 monoclonal antibody
taxane
Non-small cell lung cancer
NSW
2200 - Bankstown - Bankstown-Lidcombe Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Cancer Research SA (COMPLETED)
NCT05633654
Curative
Phase 3
Recruiting
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (
GS-US-595-6184
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3168 - Clayton - Monash Medical Centre
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4870 - Cairns - Cairns Base Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05307705
Advanced
Phase 1
Recruiting
A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation (
PIKASSO-01
)
PI3Kalpha H1047R inhibitor
Breast cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
SA
5000 - Adelaide - Cancer Research SA
NCT05142189
Advanced
Phase 1
Recruiting
LuCa-MERIT-1
: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
vaccine therapy,MAGE-A3/CLDN6/KK-LC-1/PRAME/MAGE-A4/MAGE-C1-targeting
Non-small cell lung cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Cancer Research SA
NCT04534205
Advanced
Phase 2 / Phase 3
Recruiting
An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (
AHEAD-MERIT
)
anti-PD-1 monoclonal antibody
vaccine therapy,HPV-E6/HPV-E7-targeting
Head and neck cancer
Head and neck squamous cell carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2500 - Wollongong - Wollongong Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital (WITHDRAWN)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (WITHDRAWN)
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Cancer Research SA
5042 - Bedford Park - Flinders Medical Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (29)
Recruitment Country and State
SA (28)
NSW (25)
QLD (18)
VIC (18)
WA (10)
TAS (3)
NZ (1)
Phase
Phase 1 (14)
Phase 1 / Phase 2 (6)
Phase 2 (2)
Phase 2 / Phase 3 (2)
Phase 3 (5)
Trial Type
Advanced (26)
Curative (2)
Radonc (1)
Cancer Therapy Class
PD-1/PD-L1
41%
PD-L1
24%
PD-1
24%
VEGFA
21%
oestrogen axis
14%
EGFR
10%
ER
10%
ERBB3
7%
CDK2
7%
CDK4
7%
CDK6
7%
SMO
7%
ERBB2
7%
Trop2
7%
CLDN6
7%
KIF18A
3%
KAT6A
3%
CD70
3%
MET
3%
CCR8
3%
CEACAM5
3%
ER alpha
3%
FR-alpha
3%
VEGF
3%
B7H3
3%
CTLA4
3%
PI3Kalpha H1047R
3%
MAGE-A3
3%
MAGE-A4
3%
MAGE-C1
3%
PRAME
3%
HPV-E6
3%
HPV-E7
3%
Facility
5000 - Adelaide - Cancer Research SA (29)
3168 - Clayton - Monash Medical Centre (8)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (6)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (6)
2109 - North Ryde - Macquarie University Hospital (5)
3000 - Melbourne - Peter MacCallum Cancer Centre (5)
3004 - Melbourne, Southbank - Alfred Health (4)
6009 - Nedlands - One Clinical Research (4)
3199 - Frankston - Peninsula Health Frankston Hospital (4)
2500 - Wollongong - Wollongong Hospital (4)
4215 - Southport - Tasman Oncology (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
2031 - Randwick - Scientia Clinical Research Ltd (3)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
3021 - St Albans - Western Health - Sunshine Hospital (3)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (3)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (3)
5042 - Bedford Park - Flinders Medical Centre (3)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (2)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (2)
7000 - Hobart - Royal Hobart Hospital (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
2500 - Wollongong - Cancer Care Wollongong (2)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
4215 - Southport - Gold Coast University Hospital (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
4812 - Hyde Park - Icon Cancer Centre Townsville (2)
4870 - Cairns - Cairns Base Hospital (2)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
2200 - Bankstown - Bankstown-Lidcombe Hospital (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
6009 - Nedlands - Linear Clinical Research (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2217 - Kogarah - St George Private Hospital (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
2139 - Concord - Concord Repatriation General Hospital (1)
5065 - Toorak Gardens - Burnside War Memorial Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
6009 - Nedlands - Hollywood Private Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
2830 - Dubbo - Dubbo Base Hospital (1)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2060 - North Sydney - Mater Hospital (1)
2217 - Kogarah - St George Hospital (1)
2480 - Lismore - Lismore Base Hospital (1)
3066 - Epping - Northern Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
3135 - Ringwood East - Maroondah Hospital (1)
3630 - Shepparton - Goulburn Valley Health (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
4215 - Southport - ICON Cancer Care (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2541 - Nowra - Shoalhaven District Memorial Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
6150 - Murdoch - GenesisCare Murdoch (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
Cancer Type
Cancer
Solid tumour
Breast cancer
Lung cancer
Respiratory tract cancer
Thoracic cancer
Non-small cell lung cancer
Gynaecological cancer
Ovarian cancer
Endometrial cancer
Gastrointestinal cancer
Upper gastrointestinal cancer
Breast adenocarcinoma
Triple-negative breast cancer
Cervical cancer
Colorectal cancer
HPV-related cancer
HPV16-positive cancer
Lower gastrointestinal cancer
Melanoma
Viral-related cancer
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Pancreatic cancer
Pancreatobiliary cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Epithelial Ovarian Cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Platinum resistant ovarian cancer
Haematological malignancy
Colorectal adenocarcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Mucosal melanoma
Oesophageal cancer
Uveal melanoma
Hepatobiliary cancer
Hepatocellular carcinoma
Cutaneous melanoma
Skin cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy